Institutional members access full text with Ovid®

Share this article on:

The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data

Thönnes, Stefanie; Friedel, Heiko; Fröhlich, Heike

European Journal of Gastroenterology & Hepatology: May 2017 - Volume 29 - Issue 5 - p 503–508
doi: 10.1097/MEG.0000000000000819
Original Articles: Hepatitis

Aim/Objectives/Background Chronic hepatitis C (CHC) virus infection is a leading cause of liver-related morbidity and mortality. In Germany, as in many other countries, there is a lack of comprehensive epidemiological data. Routine data from sickness funds can support the estimation of the true prevalence and incidence of CHC.

Methods In this article, the results of annual and quarterly analyses of prevalence and incidence for the years 2007–2013 are presented using data of several German sickness funds.

Results Overall, the prevalence rate remained relatively stable at 0.2%, which is lower than the general assumption for Germany of 0.3%.

Conclusion We found that despite the introduction of the breakthrough designated triple therapies with telaprevir or boceprevir in 2011, there was no increase of prevalence or incidence between 2010 and 2011.

Supplemental Digital Content is available in the text.

aTeam Gesundheit GmbH, Essen

bAbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

Correspondence to Stefanie Thönnes, MSc, Team Gesundheit GmbH, Rellinghauser Straße 93, 45128 Essen, Germany Tel: +49201890 70704; fax: +49201890 7055; e-mail:

Received October 4, 2016

Accepted November 21, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.